CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker

被引：4
|
作者：
Li, Cuicui [1 ]
Zhang, Litian [1 ]
Jin, Qiqi [1 ]
Jiang, Haoyun [1 ]
Wu, Chongyang [1 ]
机构：
[1] Lanzhou Univ, Dept Gastroenterol, Hosp 2, Lanzhou 730000, Peoples R China
来源：
BIOMARKERS IN MEDICINE | 2023年 / 17卷 / 12期
基金：
中国国家自然科学基金;
关键词：
adenosine; biomarker; CD39; CD8(+) TIL; exhaustion; immunosuppression; PD-1; tumor microenvironment; CD8; T-CELLS; ECTONUCLEOTIDASES CD39; IMMUNE-RESPONSES; PD-L1; EXPRESSION; ADENOSINE; RECEPTOR; CD73; METABOLISM; SUBSETS; CANCER;
D O I：
10.2217/bmm-2023-0202
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
As a regulator of the dynamic balance between immune-activated extracellular ATP and immunosuppressive adenosine, CD39 ectonucleotidase impairs the ability of immune cells to exert anticancer immunity and plays an important role in the immune escape of tumor cells within the tumor microenvironment. In addition, CD39 has been studied in cancer patients to evaluate the prognosis, the efficacy of immunotherapy (e.g., PD-1 blockade) and the prediction of recurrence. This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.
引用
收藏
页码：563 / 576
页数：14
相关论文
共 50 条
  • [31] ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
    Rocconi, Rodney P.
    Stanbery, Laura
    Tang, Min
    da Silva, Luciana Madeira
    Walter, Adam
    Monk, Bradley J.
    Herzog, Thomas J.
    Coleman, Robert L.
    Manning, Luisa
    Wallraven, Gladice
    Horvath, Staci
    Bognar, Ernest
    Senzer, Neil
    Brun, Scott
    Nemunaitis, John
    COMMUNICATIONS MEDICINE, 2022, 2 (01):
  • [32] Transcription factor YY1 and the retinoblastoma protein are downstream targets of CD39/ENTPD1 signaling pathways during liver regeneration
    Wu, Y
    Imai, M
    Sun, XF
    Csizmadia, E
    Enjyoji, K
    Choi, CH
    Robson, SC
    Usheva, A
    HEPATOLOGY, 2005, 42 (04) : 642A - 643A
  • [33] CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice
    Sun, Xiaofeng
    Wu, Yan
    Gao, Wenda
    Enjyoji, Keiichi
    Csizmadia, Eva
    Mueller, Christa E.
    Murakami, Takashi
    Robson, Simon C.
    GASTROENTEROLOGY, 2010, 139 (03) : 1030 - 1040
  • [34] ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
    Rodney P. Rocconi
    Laura Stanbery
    Min Tang
    Luciana Madeira da Silva
    Adam Walter
    Bradley J. Monk
    Thomas J. Herzog
    Robert L. Coleman
    Luisa Manning
    Gladice Wallraven
    Staci Horvath
    Ernest Bognar
    Neil Senzer
    Scott Brun
    John Nemunaitis
    Communications Medicine, 2
  • [35] Delivery of ENTPD1 (CD39) and 5NTE1 (CD73) by Exosome or Recombinant Anti-Inflammatory FusioN (RAIN) as a Potential Strategy for the Treatment of Rheumatoid Arthritis
    Finn, Jonathan D.
    Snoek, Susanne
    van Ittersum, Jan
    van Baarsen, Lisa
    Broekstra, Niels
    Feijt, Carola
    Tak, Paul P.
    Vervoordeldonk, Margriet J.
    MOLECULAR THERAPY, 2014, 22 : S265 - S265
  • [36] Expression of CD39/Entpd1 on granuloma-composing cells and induction of Foxp3-positive regulatory T cells in sarcoidosis
    Fujimura, T.
    Kambayashi, Y.
    Aiba, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2013, 38 (08) : 883 - 889
  • [37] Therapeutic Potential for CD39 in Renal Transplantation: There is Hope
    Laubach, V. E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (12) : 2567 - 2568
  • [38] Expression and function of P2X7 receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters
    Garcia-Hernandez, Mariana H.
    Portales-Cervantes, Liliana
    Cortez-Espinosa, Nancy
    Vargas-Morales, Juan M.
    Fritche Salazar, Juan F.
    Rivera-Lopez, Emmanuel
    Rodriguez-Rivera, Javier G.
    Quezada-Calvillo, Roberto
    Portales-Perez, Diana P.
    CELLULAR IMMUNOLOGY, 2011, 269 (02) : 135 - 143
  • [39] Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
    Rodney P. Rocconi
    Laura Stanbery
    Min Tang
    Luciana Madeira da Silva
    Adam Walter
    Bradley J. Monk
    Thomas J. Herzog
    Robert L. Coleman
    Luisa Manning
    Gladice Wallraven
    Staci Horvath
    Ernest Bognar
    Neil Senzer
    Scott Brun
    John Nemunaitis
    Communications Medicine, 3
  • [40] CD39 target practice
    Newman, Debra K.
    BLOOD, 2013, 121 (16) : 3061 - 3062
12345